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OBJECTIVE: To assess the prevalence and burden of
ADHD in the Nordic countries. METHODS: Literature
databases were searched for publications relevant to the
study countries and keywords. The time frame was 1987
to 2002. The keywords were ADHD, DAMP, MBD, and
HKD. RESULTS: There were six prevalence studies in
children aged between six and nine years. The prevalence
rates of DAMP ranged between 2.8 and 7.1%. The preva-
lence rates of ADHD ranged between 3.7 and 7.1%.
Several smaller Finnish studies reported that children 
with MBD/ADHD often transfer to special education, 
or require additional teaching at school. Finnish and
Swedish studies found that 75–80% of children with
MBD/ADHD don’t complete high school. One Swedish
study showed that 11% of children with ADHD had full
sick pension at age 22. Finnish and Norwegian pub-
lications report that 38%–47% of children with
ADHD/MBD have no friends. Fifty-three percent of the
parents in a Norwegian study said their marital problems
were associated with the child’s MBD. Finnish and Nor-
wegian studies found that the child’s dysfunction caused
the family extra burden in daily activities and a change
of their work situation or time. Swedish, Danish, and
Finnish studies have shown that ADHD is associated with
long-term psychiatric consequences. In Denmark, 24% of
children with ADHD had been given a lifetime psy-
chiatric diagnosis at age 23. Finnish, Norwegian, and
Swedish studies have reported an over-representation 
of ADHD in prison populations. Moreover, children with
ADHD are especially exposed to sexual offences, and
commit such crimes more often than others. CONCLU-
SIONS: The Nordic data on prevalence of ADHD is in
concordance with international ﬁgures. Although some 
of the studies were small and not randomised, the 
results indicate that ADHD is associated with a great
burden for the affected children, their families, and the
environment.
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Compliance to treatment is a key success factor to reduce
hospitalisations in schizophrenic patients. Conventional
antipsychotics (e.g., haloperidol) are effective in reduc-
ing positive symptoms of schizophrenia, and can cause 
multiple side effects (extrapyramidal symptoms, tardive
dyskinesia). Atypical antipsychotics with daily oral
administration (risperidone, olanzapine, clozapine) show
improved efﬁcacy and tolerability compared to con-
ventional neuroleptics. Conventional depots have been
shown to increase compliance and reduce the risk of
relapse over oral conventional treatments. Long-acting
risperidone (LA-RIS), administered intramuscularly once
every two weeks, is the ﬁrst to combine the beneﬁts of a
long-acting formulation with those of an atypical antipsy-
chotic. OBJECTIVE: To assess cost-effectiveness of 
LA-RIS versus oral olanzapine (OLA) and haloperidol
decanoate (HAL-D) in recently diagnosed schizophrenic
patients in the perspective of the Italian National Health
care System (NHS). METHODS: A French decision tree
model was adapted to the Italian setting: outcome prob-
abilities and cost estimates were based on published 
data, and supplemented with expert opinion. Only direct
medical costs were considered. For LA-RIS (not yet mar-
keted in Italy), 3 different price hypotheses were tested
(€100–125–150/injection q2weeks). Effectiveness mea-
sures were relapse-free patients and patients maintained
on the same treatment for 2 years. RESULTS: LA-RIS was
found dominant versus HAL-D in all three hypotheses
tested. Versus OLA (10mg/day), LA-RIS cost-
effectiveness ratios ranged from dominance to a
maximum of €17,544/2 years per incremental relapse-free
patient. Sensitivity analysis showed that results were
robust over a wide range of parameters tested, including
variation of the daily dose of OLA to account for current
medical practice in Italy according to the results of the
RODOS papers (13.5mg/day). CONCLUSIONS: The
model indicates that in recently diagnosed patients, 
LA-RIS is cost-saving versus HAL-D and cost-saving/
cost-effective vs. OLA and should be preferred as a treat-
ment option over oral atypicals and conventional depots,
in the perspective of the Italian NHS.
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OBJECTIVES: The occurrence of dyslipidemia, glucose
intolerance and weight gain may lead to an increased 
risk for developing Diabetes and coronary heart disease
(CHD) during therapy with atypical antipsychotics. These
complications directly inﬂuence an antipsychotic agent’s
cost-effectiveness. One method for outcome assessment is
to capture these effects with the combined endpoint of
metabolic syndrome (MetS) and, using epidemiological
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risk prediction methods, estimate a predicted risk of dia-
betes and CHD. The economic evaluation thus captured
patient-relevant outcomes of MetS or diabetes/CHD
events avoided. METHODS: MetS was deﬁned according
to NCEP (ATPIII) guidelines, with modiﬁcations reﬂect-
ing clinically meaningful changes in risk factors. Lab 
measures were derived from a randomised double-blind,
head-to-head trial. The cumulative incidence of MetS was
computed using Kaplan-Meier analysis and compared
across treatment arms for 6 months of follow-up. The 5-
year diabetes and CHD risks were estimated from each
individual patient’s risk factor proﬁle for diabetes and
CHD using a published logistic regression and Weibull
model, respectively. Resource utilisation and costs were
derived from the underlying trial and published data.
Cost analysis was based on a Swedish third party payer
perspective. RESULTS: The results showed a 65% rela-
tive risk reduction (RRR) in MetS incidence at 6 months,
a 30% RRR in diabetes and 22% RRR in CHD incidence
at 5 years for Aripiprazole versus Olanzapine. For a hypo-
thetical cohort of 1000 patients switched from Olanzap-
ine to Aripiprazole, at study endpoint 124 events of MetS,
37 events of diabetes and 6 events of CHD are avoided,
showing cost savings due to reduced medical treatment
of side-effects of SEK 101.360 for MetS, 3.035.000 SEK
for Diabetes and 880.000 SEK for CHD. CONCLU-
SIONS: The results highlight a medical and economic
beneﬁt from maintenance therapy of Aripiprazole versus
Olanzapine, reﬂected by lower costs and a reduced inci-
dence of MetS, Diabetes and CHD.
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OBJECTIVE: Although schizophrenia is a common 
and disabling medical condition, little is known about 
its impact on health-related quality of life (HRQoL) in
Asians. We therefore characterized HRQoL in outpatients
with schizophrenia in Singapore, and identiﬁed factors
that inﬂuenced HRQoL in these patients. METHODS: A
consecutive sample of outpatients with schizophrenia
seen in the Institute of Mental Health in Singapore com-
pleted a standardized English or Chinese questionnaire
containing the Schizophrenia Quality of Life Scale
(SQLS), the Short Form 36 Health Survey (SF-36) and the
Health Utilities Index Mark 3 (HUI3) classiﬁcation
system. Patients were assessed for psychiatric symptoms
using a standard checklist, and socio-economic and clin-
ical variables were collected through patient interviews
and data extraction from medical records. Subjects’ SF-
36 scores were compared with adjusted Singaporean pop-
ulation norms. Factors inﬂuencing HRQoL measured by
these instruments were identiﬁed using stepwise multiple
linear regression models. RESULTS: Two hundred two
outpatients with schizophrenia completed survey ques-
tionnaires (English-speaking: n = 140). Mean (SD) age of
the subjects was 37.8 (10.2) years, and 52% were female.
The majority of the subjects were ethnic Chinese (83.7%).
The mean (SD) duration of schizophrenia was 8.4 (7.4)
years, and 30.7% of subjects reported hospitalization in
a psychiatric ward in the 3 months preceding the survey.
Mean SF-36 scores of the subjects were 4.7 to 37.2 points
lower than adjusted Singaporean population norms (p <
0.01 for all comparisons, one-sample t-tests). Better
HRQoL in these subjects (in stepwise regression models)
was associated with less psychiatric symptoms, increasing
age and duration of illness, less years of education, pres-
ence of chronic medical conditions and usage of English
questionnaires. CONCLUSIONS: Outpatients with schiz-
ophrenia in Singapore experienced clinically important
reductions in HRQoL; both disease related and other
variables inﬂuenced HRQoL in these patients.
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OBJECTIVES: In a 6-week randomized, double-blind
trial, olanzapine was associated with signiﬁcant increases
in triglycerides, low-density lipoprotein cholesterol
(LDL), and total cholesterol (TC), while ziprasidone 
was not. We compared changes in risk of coronary heart
disease (CHD) in olanzapine- and ziprasidone-treated
patients in this trial. METHODS: We analyzed data from
trial participants aged ≥30 years using a Framingham
data-based algorithm (Circulation 1998; 97: 1837–1847)
that calculates percentage risk of CHD over 10 years from
age, gender, smoking status, presence of diabetes, high-
density lipoprotein cholesterol (HDL), LDL or TC, and
diastolic and systolic blood pressures. Changes from base-
line to endpoint in percentage age-adjusted risk of CHD
for men and women in ziprasidone and olanzapine treat-
ment groups were compared using ANCOVA. RESULTS:
Mean age was approximately 42 years for both the
ziprasidone (range 30 to 55) and olanzapine (range 30 to
59) groups. In olanzapine-treated men (n = 55), risk of
CHD increased by 0.8% from a baseline of 4.2% while
in ziprasidone-treated men (n = 44) risk decreased by
0.2% from a baseline of 4.5% (p < 0.05). Olanzapine-
treated females (n = 18) had a 0.2% decrease in risk (base-
line, 3%) while ziprasidone-treated females (n = 21) had
a 0.4% increase (baseline, 2.5%) (p = NS). Analysis of
treatment-associated changes in lipids in patients of all
ages by gender found signiﬁcant changes in TC, LDL, and
triglycerides in olanzapine-treated men of all ages (n = 82)
versus ziprasidone-treated men (n = 69) (p < 0.005), with
